title: Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?
abstract: Pre-eclampsia is a vascular disorder of pregnancy where anti-angiogenic factors, systemic inflammation and oxidative stress predominate, but none can claim to cause pre-eclampsia. This review provides an alternative to the 'two-stage model' of pre-eclampsia in which abnormal spiral arteries modification leads to placental hypoxia, oxidative stress and aberrant maternal systemic inflammation. Very high maternal soluble fms-like tyrosine kinase-1 (sFlt-1 also known as sVEGFR) and very low placenta growth factor (PlGF) are unique to pre-eclampsia; however, abnormal spiral arteries and excessive inflammation are also prevalent in other placental disorders. Metaphorically speaking, pregnancy can be viewed as a car with an accelerator and brakes, where inflammation, oxidative stress and an imbalance in the angiogenic milieu act as the 'accelerator'. The 'braking system' includes the protective pathways of haem oxygenase 1 (also referred as Hmox1 or HO-1) and cystathionine-γ-lyase (also known as CSE or Cth), which generate carbon monoxide (CO) and hydrogen sulphide (H2S) respectively. The failure in these pathways (brakes) results in the pregnancy going out of control and the system crashing. Put simply, pre-eclampsia is an accelerator-brake defect disorder. CO and H2S hold great promise because of their unique ability to suppress the anti-angiogenic factors sFlt-1 and soluble endoglin as well as to promote PlGF and endothelial NOS activity. The key to finding a cure lies in the identification of cheap, safe and effective drugs that induce the braking system to keep the pregnancy vehicle on track past the finishing line.
authors.affiliation: Vascular Therapeutics Unit, Aston Medical School, Aston University, Birmingham, UK.
authors.forename: Asif
authors.initials: A
authors.lastname: Ahmed
authors.forename: Wenda
authors.initials: W
authors.lastname: Ramma
mesh_terms: D000818:Animals; D002248:Carbon Monoxide / Q000378:metabolism; D015195:Drug Design; D005260:Female; D006801:Humans; D006862:Hydrogen Sulfide / Q000378:metabolism; D007249:Inflammation / Q000473:pathology*; D018384:Oxidative Stress / Q000502:physiology*; D010920:Placenta / Q000378:metabolism; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000503:physiopathology*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000378:metabolism
chemical_list: C000608036:PGF protein, human; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor; D002248:Carbon Monoxide; D040281:Vascular Endothelial Growth Factor Receptor-1; D006862:Hydrogen Sulfide